Download Citation
Article Source:
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
Greenberg RN,
Hurley Y,
Dinh DV,
Mraz S,
Vera JG,
et al.
(2015)
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis.
PLOS ONE 10(10): e0138348.
https://doi.org/10.1371/journal.pone.0138348